Hypertension
📧 Sign up to get email alerts when something new happens for Hypertension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2012-02-02FDA Approved: ALISKIREN — Supplemental Application (Prasco Laboratories)
The FDA approved a supplemental application for aliskiren hemifumarate from Prasco Laboratories, making a generic version of aliskiren avail…
-
CLINICAL_TRIALS trial_result · 2012-01-31Clinical Trial Update: Study of Catheter Based Renal Denervation Therapy in Hypertension [Phase 3]
Phase 3 trial update of catheter-based renal denervation therapy for hypertension; current status is UNKNOWN.
-
CLINICAL_TRIALS trial_result · 2012-01-30Clinical Trial Update: The HERCULES Trial - A Safety and Effectiveness Study of the Herculink Elite Renal Stent to Treat Renal Artery Stenosis [NA]
This update notes the completed safety and effectiveness study (HERCULES) of the Herculink Elite Renal Stent for renal artery stenosis, with…
-
FDA approval · 2012-01-27FDA Approved: PROPRANOLOL HYDROCHLORIDE — Supplemental Application (Ipca Laboratories Limited)
FDA approved a supplemental application for propranolol hydrochloride from Ipca Laboratories Limited, finalizing a regulatory update for the…
-
FDA approval · 2012-01-27FDA Approved: PROPRANOLOL HYDROCHLORIDE — Supplemental Application (Endo USA, Inc.)
FDA approved Endo USA, Inc.'s supplemental application for propranolol hydrochloride, indicating the generic product's supplemental filing h…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2012-01-26FDA Approved: ALISKIREN — Supplemental Application (Prasco Laboratories)
FDA approved a supplemental application for a generic version of aliskiren hemifumarate by Prasco Laboratories.
-
CLINICAL_TRIALS withdrawal · 2012-01-26Clinical Trial Update: Role of Enhanced External Counterpulsation (EECP) Therapy in Patients With Resistant Hypertension [NA]
This clinical trial update reports that a study evaluating enhanced external counterpulsation (EECP) therapy for resistant hypertension has …
-
CLINICAL_TRIALS trial_result · 2012-01-26Clinical Trial Update: Controlled Release Nifedipine and Valsartan Combination Therapy in Patients With Essential Hypertension [Phase 4]
Phase 4 clinical trial update reporting the completion of a study evaluating a controlled-release nifedipine and valsartan combination for e…
-
CLINICAL_TRIALS withdrawal · 2012-01-26Clinical Trial Update: Effect of Treating Sleep Disorder Breathing in Patients With Resistant Hypertension [NA]
A clinical trial examining treating sleep-disordered breathing in patients with resistant hypertension has been withdrawn.
-
FDA approval · 2012-01-23FDA Approved: CARVEDILOL — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved Teva Pharmaceuticals USA, Inc.'s supplemental application for carvedilol, a generic beta-blocker, for a new or expanded generic…
-
CLINICAL_TRIALS trial_result · 2012-01-23Clinical Trial Update: Seasonal Variation of Ambulatory Blood Pressure
Completed clinical trial investigating seasonal variation in ambulatory blood pressure with results posted.
-
FDA approval · 2012-01-20FDA Approved: MICARDIS HCT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for MICARDIS HCT (telmisartan/hydrochlorothiazide) submitted by Boehringer Ingelheim Pharmaceuticals…
-
FDA approval · 2012-01-19FDA Approved: LOTENSIN — Supplemental Application (Validus Pharmaceuticals LLC)
FDA approved a supplemental application for LOTENSIN (benazepril hydrochloride) submitted by Validus Pharmaceuticals LLC.
-
FDA approval · 2012-01-19FDA Approved: MICARDIS HCT — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental application for MICARDIS HCT (telmisartan and hydrochlorothiazide) by Boehringer Ingelheim Pharmaceuticals, Inc.…
-
FDA approval · 2012-01-19FDA Approved: LOTREL — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Lotrel, a combination of amlodipine besylate and benazepril hydrochloride, submitted by Nova…
-
FDA approval · 2012-01-19FDA Approved: BENAZEPRIL HYDROCHLORIDE AND HYDROCHLOROTHIAZIDE — Supplemental Application (Padagis US LLC)
FDA approved a supplemental application for benazepril hydrochloride and hydrochlorothiazide (Padagis US LLC), resulting in updated labeling…
-
FDA approval · 2012-01-19FDA Approved: TRIBENZOR — Supplemental Application (Cosette Pharmaceuticals, Inc.)
FDA approved a supplemental application for Tribenzor, a fixed-dose combination of olmesartan medoxomil, amlodipine besylate, and hydrochlor…
-
FDA approval · 2012-01-19FDA Approved: TRIAMTERENE AND HYDROCHLOROTHIAZIDE — Supplemental Application (BluePoint Laboratories)
FDA approved a supplemental application for Triamterene and Hydrochlorothiazide from BluePoint Laboratories, authorizing changes to the prev…
-
FDA approval · 2012-01-19FDA Approved: METOPROLOL TARTRATE AND HYDROCHLOROTHIAZIDE — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical's original application for metoprolol tartrate and hydrochlorothiazide as a generic fixed-dose combination p…
-
FDA approval · 2012-01-19FDA Approved: HYDROCHLOROTHIAZIDE — Supplemental Application (Teva Pharmaceuticals USA, Inc.)
FDA approved a supplemental application for Hydrochlorothiazide (generic) submitted by Teva Pharmaceuticals USA, Inc., under the ANDA progra…
-
FDA approval · 2012-01-18FDA Approved: EXFORGE — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Exforge (amlodipine besylate and valsartan) to update the labeling for this antihypertensive…
-
FDA approval · 2012-01-18FDA Approved: DIOVAN HCT — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for Diovan HCT (valsartan and hydrochlorothiazide) submitted by Novartis Pharmaceuticals Corpora…
-
FDA approval · 2012-01-18FDA Approved: BENICAR HCT — Supplemental Application (Cosette Pharmaceuticals, Inc.)
FDA approved a supplemental application for Benicar HCT (olmesartan medoxomil-hydrochlorothiazide) from Cosette Pharmaceuticals, Inc.
-
FDA approval · 2012-01-18FDA Approved: AVAPRO — Supplemental Application (Sanofi-Aventis U.S. LLC)
The FDA approved a supplemental application for AVAPRO (irbesartan) submitted by Sanofi-Aventis U.S. LLC.
-
FDA label_change · 2012-01-18FDA Approved: MICARDIS — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)
FDA approved a supplemental labeling change for Micardis (telmisartan) submitted by Boehringer Ingelheim Pharmaceuticals, Inc.